AstraZeneca has raised billions of dollars in short-term cash by pawning off the rights to a growing list of its drugs that it says are not important for its long-term future.
Pfizer just this week agreed to pay $1.5 billion for AstraZeneca’s antibiotics portfolio. But the U.K. drugmaker is trying a new twist on its asset sales practice, putting its U.S. headquarters in Delaware up for sale with plans to lease it back to pick up some money.
The campus in Fairfax, DE, went on the market this week, Delawareonline reported. An AstraZeneca spokesperson told the news service that the drugmaker is looking at a number of options, including redeveloping the site.
“In order to fully explore this [redevelopment] possibility, AstraZeneca will be soliciting bids from real estate developers in the coming months and that requires us putting the site on the market for sale,” AstraZeneca spokeswoman Abigail Bozarth told the publication.
The move comes as AstraZeneca is in the midst of a variety of cost-cutting moves and as CEO Pascal Soriot works feverishly to build up the drugmaker’s top and bottom lines. The company in April announced it intended to make $1.1 billion in cost cuts and followed that up in May by whacking the jobs of about 1,600 U.S. contract sales reps.
The company, following an industry trend, also has been shedding products that fall outside the therapeutic fields in which it has the most potential, picking up much needed cash along the way.
Pfizer is buying 5 antibiotics, including the rights to two still under development. In June, AstraZeneca agreed to sell the U.S. rights to 7 drugs to South Africa’s Aspen Pharmacare for up to $770 million. That deal followed many others. It sold a partnership for $500 million to Eli Lilly on an Alzheimer’s drug, and also sold Movantik, its treatment for opioid-induced constipation to Japan’s Daiichi Sankyo, for another $200 million.
While it is unclear how much the real estate deal might bring, property experts told the publication that a sale for redeveloping the campus might actually yield a substantial return, given its location and how much underutilized space there is. AstraZeneca has actually taken several buildings down on the site, following an earlier round of cost-cutting and layoffs.
By Eric Palmer
Souce: Fierce Pharma
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.